Richard Thomas Williams - 01 Mar 2024 Form 4 Insider Report for Kinnate Biopharma Inc.

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: N/A
Reported as of: 01 Mar 2024
Net transaction value: -$1,445
SEC form: 4
Accepted by SEC: 05 Mar 2024, 17:00:19 UTC
Prior SEC filing: 05 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark A. Meltz, as attorney-in-fact

Key filing fact

Richard Thomas Williams filed Form 4 for Kinnate Biopharma Inc. on 05 Mar 2024.

Key facts

This page summarizes Richard Thomas Williams's Form 4 filing for Kinnate Biopharma Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Mar 2024, 17:00.

Change

Previous filing in this sequence was filed on 05 Dec 2023.
Current net transaction value: -$1,445.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNTE transaction

Common Stock

Tax liability

Transaction value: $1,445
Shares: -558
Change %: -0.82%
Price: $2.59
Shares after: 67,588
Date: 01 Mar 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of restricted stock units ("RSUs") granted to the Reporting Person by the Issuer.

Footnote F2

Includes 15,625 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.